Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -29.10% is 75% above its 5-year average of -115.37%, near the high end of its 5-year range (-373.60%–-29.10%).
56.28% above its 12-month average of -66.56%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.49%.
RETURN ON ASSETS (ROA)
-29.10%
RETURN ON ASSETS (ROA) AVG TTM
-66.56%
RETURN ON ASSETS (ROA) AVG 3Y
-142.45%
RETURN ON ASSETS (ROA) AVG 5Y
-115.37%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+56.28%
CURRENT VS 3Y AVG
+79.57%
CURRENT VS 5Y AVG
+74.78%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+9.74%
vs the sector median at left
Aprea Therapeutics, Inc.
Market Cap
$7.95M
Return on Assets (ROA)
-29.10%
TTM Avg
-66.56%
3Y Avg
-142.45%
5Y Avg
-115.37%
Market Cap
$7.92M
Return on Assets (ROA)
86.37%
TTM Avg
-66.33%
3Y Avg
-66.09%
5Y Avg
-69.89%
Market Cap
$8.20M
Return on Assets (ROA)
-269.47%
TTM Avg
-172.22%
3Y Avg
-300.06%
5Y Avg
-300.06%
Market Cap
$8.18M
Return on Assets (ROA)
N/A
TTM Avg
-103.86%
3Y Avg
-117.64%
5Y Avg
-138.14%
Market Cap
$7.76M
Return on Assets (ROA)
-76.12%
TTM Avg
-177.28%
3Y Avg
-394.98%
5Y Avg
-300.85%
Market Cap
$8.15M
Return on Assets (ROA)
-381.53%
TTM Avg
-330.40%
3Y Avg
-209.86%
5Y Avg
-253.27%
Market Cap
$7.76M
Return on Assets (ROA)
-74.50%
TTM Avg
-220.41%
3Y Avg
-182.97%
5Y Avg
-158.82%
Market Cap
$7.56M
Return on Assets (ROA)
-74.58%
TTM Avg
-69.72%
3Y Avg
-51.64%
5Y Avg
-52.44%
Market Cap
$8.38M
Return on Assets (ROA)
-23.11%
TTM Avg
-173.03%
3Y Avg
-145.25%
5Y Avg
-97.33%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $7.95M | -29.10% | -66.56% | -142.45% | -115.37% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | 86.37% | -66.33% | -66.09% | -69.89% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.20M | -269.47% | -172.22% | -300.06% | -300.06% |
| HeartSciences Inc. (HSCS)vs › | $8.18M | N/A | -103.86% | -117.64% | -138.14% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.76M | -76.12% | -177.28% | -394.98% | -300.85% |
| GT Biopharma, Inc. (GTBP)vs › | $8.15M | -381.53% | -330.40% | -209.86% | -253.27% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.76M | -74.50% | -220.41% | -182.97% | -158.82% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.56M | -74.58% | -69.72% | -51.64% | -52.44% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.38M | -23.11% | -173.03% | -145.25% | -97.33% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.50M | -106.57% | -92.47% | -315.20% | -267.86% |
ROA
-29.1%
ROE
-32.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -79.08% |
| 2024-12-31 | -54.04% |
| 2023-12-31 | -63.08% |
| 2022-12-31 | -373.60% |
| 2021-12-31 | -64.30% |
| 2020-12-31 | -58.10% |
| 2019-12-31 | -21.00% |
| 2018-12-31 | -23.52% |
| 2017-12-31 | -61.35% |
